Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?

 

 Permissions and Reprints

Abstract

Background The Creutzfeldt-Jakob disease (CJD) is a spongiform encephalopathy that manifests as a rapidly progressive dementia syndrome. Currently, CJD has no cure, and many patients die within the first year, but some drugs are being studied as options for managing this condition.

Objective To evaluate the effectiveness of pharmacological treatments offered to patients with CJD as a means to increase survival and reduce cognitive deterioration.

Methods A systematic review of the literature was performed using 4 independent reviewers and 1 extra reviewer to resolve possible divergences in the search and analysis of papers indexed in MedLINE (PubMed), SciELO and Lilacs databases. The Medical Subject Heading (MeSH) terms used were: prion diseases, Creutzfeldt-Jakob disease, pharmacologic therapy, therapeutics, quinacrine, doxycycline, flupirtine, and pentosan polysulfate, with the Boolean operators AND and OR. This search included controlled clinical trials, uncontrolled clinical trials, and case series published from the year 2000 onwards, in the English language.

Results A total of 85 papers were found using the descriptors used. At the end of the selection analyses, 9 articles remained, which were analyzed fully and individually.

Conclusions None of the drugs evaluated proved significantly effective in increasing survival in patients with CJD. Flupirtine appears to have a beneficial effect in reducing cognitive deterioration in patients with CJD. However, additional studies are needed to establish better evidence and therapeutic options for the management of patients with CJD.

Resumo

Antecedentes A doença de Creutzfeldt-Jakob (DCJ) é uma encefalopatia espongiforme que se manifesta como síndrome demencial rapidamente progressiva. Atualmente, a DCJ não possui cura e muitos pacientes morrem no primeiro ano de doença, mas alguns medicamentos vêm sendo estudados como opções no manejo desta condição.

Objetivo Avaliar a eficácia dos tratamentos farmacológicos oferecidos aos pacientes com DCJ no aumento de sobrevida e na redução da deterioração cognitiva.

Métodos Foi realizada uma revisão sistemática da literatura utilizando 4 revisores independentes e 1 extra para resolver divergências eventuais na busca e na análise de trabalhos indexados nas bases de dados MedLINE (via PubMed), SciELO e Lilacs. Os termos Medical Subjects Heading (MeSH) utilizados foram: prion diseases, creutzfeldt jakob disease, pharmacologic therapy, therapeutics, quinacrine, doxycycline, flupirtine e pentosan polysulfate, com os operadores booleanos AND e OR. Essa pesquisa incluiu ensaios clínicos controlados, não controlados e séries de casos, publicados a partir do ano 2000 no idioma inglês.

Resultados Ao todo, foram encontrados 85 trabalhos através dos descritores utilizados. Ao final das análises de seleção, restaram 9 artigos, que foram analisados na íntegra individualmente.

Conclusões Nenhuma das drogas avaliadas se mostrou significativamente eficaz no aumento da sobrevida dos pacientes com DCJ. A flupirtina parece ter um efeito benéfico na redução da deterioração cognitiva dos pacientes com DCJ. Entretanto, estudos adicionais são necessários para o estabelecimento de melhores evidências e opções terapêuticas para o manejo dos pacientes com DCJ.

Authors' Contributions

LHLM: conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, writing-original draft, writing-review & editing; AFPHO, DMC, GMFS, JGMM, JACJ, PTMBQ, RMAJ, SPLF: conceptualization, data curation, formal analysis, investigation, methodology, project administration, writing-original draft; HMAM: conceptualization, project administration, validation, visualization, writing-original draft, writing-review & editing.

Publication History

Received: 27 August 2021

Accepted: 31 October 2021

Article published online:
17 October 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

• References

• 1 Geschwind MD. Prion Diseases. Continuum (Minneap Minn) 2015; 21 (6 Neuroinfectious Disease): 1612-1638
  Google Scholar
• 2 Johnson RT. Prion diseases. Lancet Neurol 2005; 4 (10) 635-642
  CrossrefPubMedGoogle Scholar
• 3 Groveman BR, Foliaki ST, Orru CD. et al. Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids. Acta Neuropathol Commun 2019; 7 (01) 90
  CrossrefPubMedGoogle Scholar
• 4 Sharma S, Mukherjee M, Kedage V, Muttigi MS, Rao A, Rao S. Sporadic Creutzfeldt-Jakob disease–a review. Int J Neurosci 2009; 119 (11) 1981-1994
  CrossrefPubMedGoogle Scholar
• 5 Ministério da Saúde. Protocolo de notificação e investigação da doença de Creutzfeldt-Jakob com foco na identificação da nova variante. Brasília, DF; 2018
  Google Scholar
• 6 Sigurdson CJ, Bartz JC, Glatzel M. Cellular and Molecular Mechanisms of Prion Disease. Annu Rev Pathol 2019; 14 (01) 497-516
  CrossrefPubMedGoogle Scholar
• 7 Terry C, Wadsworth JDF. Recent Advances in Understanding Mammalian Prion Structure: A Mini Review. Front Mol Neurosci 2019; 12: 169
  CrossrefPubMedGoogle Scholar
• 8 Maddox RA, Person MK, Blevins JE. et al. Prion disease incidence in the United States: 2003-2015. Neurology 2020; 94 (02) e153-e157
  CrossrefPubMedGoogle Scholar
• 9 Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis 2020; 20 (01) e2-e10
  CrossrefPubMedGoogle Scholar
• 10 Al-Ansari A, Robertson NP. Creutzfeldt-Jacob disease: new directions in diagnosis and therapeutics. J Neurol 2017; 264 (05) 1029-1031
  CrossrefPubMedGoogle Scholar
• 11 Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006; 63 (04) 497-501
  CrossrefPubMedGoogle Scholar
• 12 Vetrugno V, Puopolo M, Cardone F, Capozzoli F, Ladogana A, Pocchiari M. The future for treating Creutzfeldt–Jakob disease. Expert Opin Orphan Drugs 2015; 3 (01) 57-74
  CrossrefGoogle Scholar
• 13 Appleby BS, Yobs DR. Symptomatic treatment, care, and support of CJD patients. In: Pocchiari M, Manson J. Handbook of Clinical Neurology. Cambridge: Elsevier; 2008: 399-408
  Google Scholar
• 14 Chen C, Dong X. Therapeutic implications of prion diseases. Biosafety Health 2021; 3 (02) 92-100
  CrossrefGoogle Scholar
• 15 Manix M, Kalakoti P, Henry M. et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus 2015; 39 (05) E2
  CrossrefPubMedGoogle Scholar
• 16 CDC's Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD). 2018 [Adapted from: a) Global surveillance, diagnosis, and therapy of human transmissible spongiform encephalopathies: Report of a WHO consultation, February 9–11, 1998, Geneva, Switzerland; b) Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009, 132; 2659–2668; and c) National CJD Research & Surveillance Unit]. Accessed 18 May 2022 on: < https://www.cdc.gov/prions/cjd/diagnostic-criteria.html>
  PubMedGoogle Scholar
• 17 Collinge J, Gorham M, Hudson F. et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8 (04) 334-344
  CrossrefPubMedGoogle Scholar
• 18 Geschwind MD, Kuo AL, Wong KS. et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013; 81 (23) 2015-2023
  CrossrefPubMedGoogle Scholar
• 19 Haïk S, Brandel JP, Salomon D. et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004; 63 (12) 2413-2415
  CrossrefPubMedGoogle Scholar
• 20 Nakajima M, Yamada T, Kusuhara T. et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004; 17 (03) 158-163
  CrossrefPubMedGoogle Scholar
• 21 Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008; 15 (05) 458-464
  CrossrefPubMedGoogle Scholar
• 22 Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009; 29 (05) 632-636
  CrossrefPubMedGoogle Scholar
• 23 Haïk S, Marcon G, Mallet A. et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13 (02) 150-158
  CrossrefPubMedGoogle Scholar
• 24 Varges D, Manthey H, Heinemann U. et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry 2017; 88 (02) 119-125
  CrossrefPubMedGoogle Scholar
• 25 Otto M, Cepek L, Ratzka P. et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 2004; 62 (05) 714-718
  CrossrefPubMedGoogle Scholar
• 26 Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98 (17) 9836-9841
  CrossrefPubMedGoogle Scholar
• 27 Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74 (10) 4894-4897
  CrossrefPubMedGoogle Scholar
• 28 Witt A, Campeau J, Sim V. Combination Therapy with Doxycycline, Chlorpromazine or Quinacrine Inhibits Prion Protein Replication in a N2A Model (P5.204). Neurology 2016;86(16):
  Google Scholar
• 29 Teruya K, Doh-Ura K. Insights from Therapeutic Studies for PrP Prion Disease. Cold Spring Harb Perspect Med 2017; 7 (03) 24-43
  CrossrefPubMedGoogle Scholar
• 30 Vogtherr M, Grimme S, Elshorst B. et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 2003; 46 (17) 3563-3564
  CrossrefPubMedGoogle Scholar
• 31 Barret A, Tagliavini F, Forloni G. et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77 (15) 8462-8469
  CrossrefPubMedGoogle Scholar
• 32 Dhar S, Bitting RL, Rylova SN. et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 2002; 51 (04) 448-466
  CrossrefPubMedGoogle Scholar
• 33 Müller WE, Romero FJ, Perovic S, Pergande G, Pialoglou P. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J Neurochem 1997; 68 (06) 2371-2377
  CrossrefPubMedGoogle Scholar
• 34 Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm (Vienna) 1999; 106 (9-10): 857-867
  CrossrefPubMedGoogle Scholar
• 35 Perovic S, Schröder HC, Pergande G, Ushijima H, Müller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997; 147 (02) 518-524
  CrossrefPubMedGoogle Scholar
• 36 Tagliavini F, Forloni G, Colombo L. et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro11Edited by J. Karn. Journal of Molecular Biology. 2000; 300 (05) 1309-22
  PubMedGoogle Scholar
• 37 Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009; 9 (01) 23-30
  CrossrefPubMedGoogle Scholar
• 38 Di Fede G, Giaccone G, Salmona M, Tagliavini F. Translational Research in Alzheimer's and Prion Diseases. J Alzheimers Dis 2018; 62 (03) 1247-1259
  CrossrefPubMedGoogle Scholar
• 39 Petrosyan R, Patra S, Rezajooei N, Garen CR, Woodside MT. Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone. Proc Natl Acad Sci U S A 2021; 118 (09) e2010213118 DOI: 10.1073/pnas.2010213118.
  CrossrefPubMedGoogle Scholar
• 40 Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 1993; 67 (02) 643-650
  CrossrefPubMedGoogle Scholar
• 41 Doh-ura K, Ishikawa K, Murakami-Kubo I. et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004; 78 (10) 4999-5006
  CrossrefPubMedGoogle Scholar
• 42 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
  Google Scholar